Life sciences briefing: Tuesday, Nov. 27, 2007

Life sciences briefing: Tuesday, Nov. 27, 2007

Featured companies: Bind Biosciences, Clarus Therapeutics, HealOr, HistroRx, Plasticell, SpinalMotion, Xenome, Yaupon Therapeutics

UPDATED: Expanded items on SpinalMotion and Plasticell. Previous items on Evalve and Excaliard have been expanded into standalone posts here and here.

Spinal-disc maker SpinalMotion arranges $14M loan facility — SpinalMotion, a Mountain View, Calif., developer of artificial spinal discs, arranged a $14 million “loan facility” — sort of a line of credit — with GE Healthcare Financial Services. The company last raised $20 million in… Continue Reading

Life sciences briefing: Friday, Aug. 17, 2007

Life sciences briefing: Friday, Aug. 17, 2007

Featured companies: Concentric Medical, Vertebration, Vision RT, Kemeta

Clotbuster Concentric Medical files for $69M IPO — Mountain View, Calif.-based Concentric Medical, which makes and markets devices for removing dangerous blood clots from the brains of stroke patients, filed to raise up to $69 million in an initial offering. The company’s devices consist of catheters that are threaded into the body’s circulatory system via the femoral artery in the groin and passed into the brain to the site… Continue Reading

Funding roundup: Announcements that got away

Funding roundup: Announcements that got away

Although I try to stay on top of events in the life sciences, announcements do sometimes manage to slip through the cracks. Some days, in fact, I end up triaging. Because the roots of this site — not to mention many of its readers — are in Silicon Valley, Bay Area events are a priority. Then come announcements from the rest of the U.S., then Asia, then Europe. Also, smaller or partial fundings tend to… Continue Reading

NanoBioDesign pulls in $1M for protein chips

NanoBioDesign, a London developer of systems that screen experimental drugs against key liver enzymes, raised $1 million (£500,000) to support manufacturing of its protein-chip devices. The funding was provided by the Imperial Innovations Group and the Capital Fund.

NanoBioDesign is focused on a class of liver enzymes known as cytochrome P450, which play an important role in metabolism. Various forms of these enzymes can greatly impact the effectiveness of drugs, depending on how quickly they break… Continue Reading